Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes pill unstiffen aging arteries?

NCT ID NCT06506422

Disease control Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether empagliflozin, a drug currently used for diabetes, can reverse the natural stiffening of arteries that happens with age. Researchers will give 80 healthy adults aged 60-80 either the drug or a placebo daily for 12 weeks. The main goal is to see if artery stiffness, measured by a standard test, improves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin (a diabetes drug, here tested for artery health)
What this could lead to
If it works, this could point toward a simple daily pill to reduce artery stiffness and potentially lower heart risks in older adults.
What could go wrong
This is an early-phase study with only 80 people, so results may not apply widely. The drug is already used for diabetes, but its effect on artery stiffness in non-diabetic people is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide consent * 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses) * Stable anti-hypertensive medication regimen (if in use) for at least 90 days * Evidence of arterial stiffening (defined as carotid-femoral PWV \>/= 8 m/s) at the time of screening visit. Exclusion Criteria: * Diabetes * BMI\>/= 45kg/m2 * Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke * Estimated glomerular filtration rate GFR \< 29 mL/min * Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin) * Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women) * Use of hormone replacement therapy * Body weight change ≥10% within the last 6 months * Uncontrolled hypertension during screening visit (\>180/110 mmHg) * Symptomatic hypotension and/or a SBP \<100 mmHg * History of ketoacidosis * High fall risk per assessment of study physician and/or safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements) * Anticipated need of prolonged fasting * History of recurrent UTIs or mycotic genital infections * Following a low-carbohydrate diet (\<20 grams/day) * Participation in regular exercise \> 3 days/week per week at a moderate or vigorous intensity * Known sensitivity to nitrate medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Arterial stiffness

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Missouri

    RECRUITING

    Columbia, Missouri, 65211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.